

The LEADING TEST
FOR EXTENDED ENDOCRINE
THERAPY DECISION-MAKING

*Coming Soon!**

Navigate new order options and test reports to help set clear endocrine therapy recommendations from the start.*

* Not currently available to order

Breast Cancer Index®

Table of Contents

- Patient Eligibility** 1
Criteria for Patient Eligibility.
- When to Order** 2
The leading test for extended endocrine therapy, with new results coming soon* to support earlier decision-making.
- How to Order** 4
Navigating new order options coming soon* for the Breast Cancer Index Test.
- Navigating Test Results** 7
Review new test reports coming soon* for the Breast Cancer Index Test.

Patient Eligibility

Patient criteria that must be met for testing.

Characteristic	
LN- or LN+ (1-3)	✓
Invasive Ductal and/or Lobular Histology	✓
HR+ (ER+ and/or PR+)	✓
Tumor Stage (pT1, pT2, pT3)	✓
Tumor Grade (1,2,3)	✓
HER2- or HER2+	✓
Pre-, Peri- or Post-menopausal	✓
Pre-treated specimen is required for testing	✓
No evidence of distant recurrence	✓

Contact Client Services for Support

📞 (877) 886-6739

✉ ClientServices@biotheranostics.com



Register for the Provider Portal

🌐 www.HologicProviderPortal.com

Scan QR Code to register

* Not currently available to order

When to Order the Breast Cancer Index® (BCI™) Test

The leading test for extended endocrine therapy, with new results coming soon* to support earlier decision-making.

Diagnosis

Primary adjuvant endocrine therapy

Year 5

Extended adjuvant endocrine therapy

Year 10

Time of Diagnosis:

As patients prepare to start endocrine therapy, **set clear expectations about their treatment plan** by ordering BCI Testing to help inform:

- **Postmenopausal** - Endocrine therapy duration: 10 years? 5 years? Even Less?*
- **Premenopausal** - Ovarian Function Suppression (OFS)?* 5 vs. 10 years of endocrine therapy?

Years 1 - 3^{1/2}:

If patients **are struggling with side effects** on endocrine therapy, order BCI Testing to help:

- Gain comfort in helping patients avoid unnecessary side effects if they have Minimal Risk of recurrence.
- Gain commitment to treatment adherence.

Approaching Year 5:

Predict whether patients are likely to benefit from extended endocrine therapy to inform whether to **extend or end endocrine therapy at the 5-year mark**.

Beyond Year 5:

For patients already continuing endocrine therapy beyond 5 years, predict if continuing to 10 is likely to be beneficial or if the additional exposure to side effects and toxicities may be avoided.

Consider the Full 0-10 Year Report

Coming Soon*

Sample Full 0-10 Year Two Page Report. The report includes patient information, test results, and a prognostic result indicating a 5% risk of late distant recurrence (LDR) with 5 total years of adjuvant endocrine therapy and no ovarian function suppression (OFS).

Sample Full 0-10 Year Two Page Report

Sample Full 0-10 Year Two Page Report (NO). The report includes patient information, test results, and a prognostic result indicating a 1.3% risk of late distant recurrence (LDR) with 5 total years of adjuvant endocrine therapy.

Consider the 5-10 Year Report

Currently the leading test for extended endocrine therapy decision-making.

Sample 5-10 Year One Page Report. The report includes patient information, test results, and a prognostic result indicating a 10.0% risk of late distant recurrence (LDR) with 5 total years of adjuvant endocrine therapy, compared to a 3.3-4.2% risk with 10 total years of adjuvant endocrine therapy.

Sample 5-10 Year One Page Report

When to Order

When to Order

How to Order BCI Testing

Navigating new order options coming soon* for the BCI Test.

BCI Testing Options

The leading test for extended endocrine therapy, with new options coming soon* to support full primary and extended adjuvant endocrine therapy planning from the start.



Breast Cancer Index® Test Requested *Select one*

Postmenopausal

Full 0-10 Year Report - Risk of overall (0-10 year) distant recurrence to inform primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

5-10 Year Report - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

Premenopausal

Full 0-10 Year Report - Risk of overall (0-10 year) distant recurrence to inform addition of OFS* to primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

5-10 Year Report - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

*Predictive results for extended endocrine therapy benefit valid upon patient remaining distant recurrence-free following completion of primary adjuvant endocrine therapy. †Ovarian function suppression.



Step 1: Menopausal Status

Distinguishing the appropriate menopausal status helps ensure individualized recurrence risk estimates are provided on the Breast Cancer Index Test report.*

Breast Cancer Index® Test Requested *Select one*

Postmenopausal

Full 0-10 Year Report - Risk of overall (0-10 year) distant recurrence to inform primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

5-10 Year Report - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

Premenopausal

Full 0-10 Year Report - Risk of overall (0-10 year) distant recurrence to inform addition of OFS* to primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

5-10 Year Report - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

*Predictive results for extended endocrine therapy benefit valid upon patient remaining distant recurrence-free following completion of primary adjuvant endocrine therapy. †Ovarian function suppression.

Guidance:

- ▶ Select a test option based on patient's menopausal status
- ▶ Postmenopausal is typically defined as 12 months without menses, or estradiol levels of less than 10pg/mL

Step 2: Full 0-10 Year* vs. 5-10 Year Report

Breast Cancer Index® Test Requested *Select one*

Postmenopausal

Full 0-10 Year Report - Risk of overall (0-10 year) distant recurrence to inform primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

5-10 Year Report - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

Premenopausal

Full 0-10 Year Report - Risk of overall (0-10 year) distant recurrence to inform addition of OFS* to primary adjuvant endocrine therapy plus risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

5-10 Year Report - Risk of late (5-10 year) distant recurrence and prediction of benefit from extended endocrine therapy.*

*Predictive results for extended endocrine therapy benefit valid upon patient remaining distant recurrence-free following completion of primary adjuvant endocrine therapy. †Ovarian function suppression.

Guidance for selecting the Full 0-10 Year Report coming soon*:

- ▶ Includes new results to support primary adjuvant endocrine therapy decisions (page 1), in addition to the extended endocrine therapy results reported (page 2)
- ▶ May be used to help guide endocrine therapy planning from the start:
 - **Postmenopausal patients:** Help inform the duration of endocrine therapy (5 years vs. 10 years vs. even less if clinically indicated)
 - **Premenopausal patients:** Help inform the addition of Ovarian Function Suppression (OFS)*, as well as 5 vs. 10 years of endocrine therapy
- ▶ Appropriate for patients who are recently diagnosed or are within 3.5 years post-diagnosis

Guidance for selecting the 5-10 Year Report:

- ▶ Includes only results to inform extended endocrine therapy
- ▶ Appropriate for patients who are approaching or already beyond the 5-year mark post-diagnosis and are distant-recurrence free
- ▶ This option most closely mirrors the existing BCI Test report

Required Information

Please be sure to include all necessary information to avoid any delays in BCI Test results.

- ▶ Complete all required fields on the order form
 - Full 0-10 Year Report Order:* Ensure Date of Discharge is indicated for Medicare patients
 - Don't forget to sign and date your order!
- ▶ Submit all required documents
 - Office Notes
 - Patient face sheet/demographics
 - Pathology reports
 - All breast associated reports including biopsy and excision
 - For LN+ patients treated with neoadjuvant therapy, attach documentation establishing pre-treatment tumor size
 - Patient insurance card

Breast Cancer Index® (BCI™) Test Requisition Form Biotheranostics, Inc.
A Hologic Company

Available for Lymph Node-Negative (LN-, N0) and Lymph Node-Positive (LN+: N1, N1mi, up to 3 Positive Nodes)
Please see page 2 for BCI patient eligibility criteria and Medicare coverage criteria under the Medicare Local Coverage Determination.

- 1 Complete all fields below.** Ordering Provider MUST sign and date this form to authorize the order. For assistance, contact Client Services at (877) 886-6739.
- 2 Attach all required documents.**
 - Office Notes / Encounters / History & Physical**

 - Discussions pertaining to the need for BCI testing
 - Discussion of how results will manage treatment
 - A medical list of any endocrine therapy prescribed
 - Pathology Reports**

 - All breast-associated reports including biopsy and excision
 - For LN+ patients treated with neoadjuvant therapy, attach documentation establishing pre-treatment tumor size
 - Patient Face Sheet**

 - Patient demographics
 - Patient Insurance Card(s)**

 - Copy of front and back
- 3 Submit completed requisition.** Ship with specimen to Biotheranostics OR fax this form to 800-266-9607 and Biotheranostics will request the specimen from Pathology. Biotheranostics, Inc., A Hologic Company
6333 Sequence Dr., San Diego, CA 92121

Navigating the BCI Test Results

Coming Soon* Full 0-10 Year Report*

Get personalized results to help set clear endocrine therapy recommendations from the start with a Full 0-10 Year Report* that includes 2 pages of results. Page 1: (Results to inform adjuvant therapy and, Page 2: Results to inform extended endocrine therapy).


POSTMENOPAUSAL

Appropriate duration of endocrine therapy: 10 years? 5 years? *Even less?**


Page 1: Results to Inform Adjuvant Therapy*

Prognostic Result: Overall distant recurrence in years 0-10 post-diagnosis.*

BCI Testing identifies node-negative (N0) patients at Minimal Risk of recurrence (<5%) even without receiving adjuvant endocrine therapy.*



For non-Minimal Risk patients, an individualized 10-year risk of recurrence is reported based on treatment with 5 years of adjuvant endocrine therapy.*



Page 2: Results to Inform Extended Endocrine Therapy

Refer to 5-10 Year Report on page 9 - these results are included as page 2 in the Full 0-10 Year Report.

Navigating the BCI Test Results

Coming Soon* Full 0-10 Year Report*


PREMENOPAUSAL

Ovarian Function Suppression (OFS)?* 5 vs. 10 years of endocrine therapy?


Page 1: Results to Inform Adjuvant Therapy*

Prognostic Result: Overall distant recurrence in years 0-10 post-diagnosis.*

BCI Testing identifies node-negative (N0) patients at Minimal Risk of recurrence (<5%) even without the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy.*



For non-Minimal Risk patients, an individualized 10-year risk of recurrence is reported based on treatment with 5 years of adjuvant endocrine therapy including those treated with OFS.*



Page 2: Results to Inform Extended Endocrine Therapy

Refer to 5-10 Year Report on page 9 - these results are included as page 2 in the Full 0-10 Year Report.


Navigating the BCI Test Results

5-10 Year Report (also included as Page 2 of Full 0-10 Year Report)

PRE- AND POST-MENOPAUSAL

5 vs. 10 years of endocrine therapy?

Results to Inform Extended Endocrine Therapy



Predictive Result

1 Reports whether the patient is likely to benefit from extended endocrine therapy. Reported as a clear **“YES”** or **“NO”**.

Prognostic Result

Reports the patient’s individual risk of late distant recurrence in years 5-10.

Depending whether the patient is likely to benefit from extended endocrine therapy (predictive result YES/NO) the report illustrates the recurrence risk if therapy is stopped at year 5 vs. continued to year 10.

2a **If Predictive YES:** Report illustrates that risk of late distant recurrence may be reduced by 58-67% if patient continues endocrine therapy for 10 years vs stopping at year 5.

2b **If Predictive NO:** Report illustrates that risk of late distant recurrence is likely to remain the same whether 5 vs. 10 years of endocrine therapy are completed.

New Options Coming Summer 2026*

Continue to order the only
guideline-recognized test to
predict extended endocrine
therapy benefit for patients
approaching the 5-year mark.^{1,2}



Order the
Breast Cancer Index Test today.

* Not currently available to order

The features and results of the Breast Cancer Index Test, to the extent they differ from the information found on the BreastCancerIndex.com website, including, but not limited to, the features concerning adjuvant endocrine therapy and ovarian function suppression: (i) are not currently available for clinical use; (ii) will be made available only after all required internal validations and regulatory requirements have been met; and (iii) is being provided herein for informational purposes only, and shall not be deemed to be an offer of availability.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed March 6, 2026. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F, et al. J Clin Oncol. Published online April 19, 2022. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2026. All rights reserved. To view the most recent and complete version of the guideline, go online to <https://ascopubs.org/jco/special/guidelines> [ascopubs.org]. ASCO makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

For the Breast Cancer Index Test Intended Use and Limitations, visit BreastCancerIndex.com

MRK-MISC002-001 Rev 1.0 © 2026 Hologic, Inc. Hologic, Biotheranostics, Breast Cancer Index, BCI, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners.

Breast Cancer Index®